Data analysis
ADVERSE EVENTS
All study participants who received any amount of the study drugs were included in the intent-to-treat population. The per-protocol-population included children who received the entire course of study medication, had a known day-28 efficacy end point, and had no major protocol deviations. The data was analyzed for efficacy in both the intention-to-treat and per-protocol populations. The efficacy endpoints were summarized by age. Safety outcomes were adverse events and abnormalities of laboratory results including liver function test and haematological indices. SPSS IBM Statistic Software version 20 was used to analyze the data at 